Danish biotech Genmab hit by ending of trial using key cancer drug

COPENHAGEN (Reuters) - Shares in Danish biotech Genmab fell by as much as 25 percent on Monday after its partner Johnson & Johnson decided to ditch a study using its blockbuster cancer drug.